NY-JEFFERIES-FINANCIAL
28.5.2020 18:04:07 CEST | Business Wire | Press release
Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease.
Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000.
“We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charities globally as this is truly a tragedy that affects all of us and, in particular, those who are most disadvantaged and in the greatest need.
The charities selected are both big and small and represent everything from food banks, child care services, assistance with PPE and other medical supplies, support for front line medical workers, assistance for afflicted military personnel, local teen centers, support for police and fire, workforce training and re-training and many other worthy areas that are most in need. We thank our employees and clients for aiding in the selection of many of these remarkable charities.
Finally, all of us at Jefferies would like to thank all the dedicated professionals working tirelessly on the front line to help those in need. They are the true heroes whom we are honored to help in Peg’s name.”
Contributions in the following amounts will be immediately distributed to these respected organizations:
NYC Mayor’s Fund | Peg’s Cure |
|
$ 150,000 |
All Hands and Hearts |
|
$ 150,000 |
American Heart Association |
$ 150,000 |
|
Bowery Mission |
$ 150,000 |
|
Hackensack Meridian Health Foundation |
$ 150,000 |
|
Houston Police Foundation |
|
$ 150,000 |
International Rescue Committee |
|
$ 150,000 |
Robin Hood Foundation |
|
$ 150,000 |
Strive |
|
$ 150,000 |
The Bass Foundation |
|
$ 150,000 |
World Central Kitchen |
|
$ 150,000 |
We Can #TogetherFromHome |
|
$ 100,000 |
Achievement First |
|
$ 100,000 |
Aktion Deutschland Hilft |
|
$ 100,000 |
Alzheimer’s Association |
|
$ 100,000 |
Ambitious About Autism |
|
$ 100,000 |
Barnardo’s |
$ 100,000 |
|
BMS Family Health and Wellness Center |
|
$ 100,000 |
Bob Woodruff Foundation |
|
$ 100,000 |
Boys & Girls Clubs of the Austin Area |
|
$ 100,000 |
Brewers Community Foundation |
|
$ 100,000 |
Buttle UK |
|
$ 100,000 |
Central Texas Food Bank |
|
$ 100,000 |
Chelsea and Westminster Hospital NHS Foundation Trust |
|
$ 100,000 |
Chrysalis |
$ 100,000 |
|
City Harvest |
$ 100,000 |
|
Citymeals on Wheels |
|
$ 100,000 |
Columbia Children's Hospital |
|
$ 100,000 |
Community Food Bank of New Jersey |
|
$ 100,000 |
Covenant House |
|
$ 100,000 |
Doctors Without Borders |
|
$ 100,000 |
East High – EOP (Education Partnership Organization) |
|
$ 100,000 |
Elmhurst Hospital Charity |
|
$ 100,000 |
Family Promise of Bergen County |
|
$ 100,000 |
FarmLink |
|
$ 100,000 |
Feeding America |
|
$ 100,000 |
Food Bank For New York City |
|
$ 100,000 |
Foodlink |
|
$ 100,000 |
Habitat for Humanity Japan |
|
$ 100,000 |
Hance Family Foundation |
|
$ 100,000 |
Humanity & Inclusion |
|
$ 100,000 |
Hunger Free America |
|
$ 100,000 |
Imperial Health Charity |
|
$ 100,000 |
Kids in Crisis |
|
$ 100,000 |
Kohka Foundation |
|
$ 100,000 |
Lahey Clinic Foundation |
|
$ 100,000 |
Mail Force Charity |
|
$ 100,000 |
Martha’s Table |
|
$ 100,000 |
Médecins Sans Frontières |
|
$ 100,000 |
Memorial Hermann Foundation |
|
$ 100,000 |
My Sister's Place |
|
$ 100,000 |
National Emergencies Trust |
|
$ 100,000 |
Navajo Nation Covid-19 Relief Fund |
|
$ 100,000 |
Nazareth Housing |
|
$ 100,000 |
Neighbourly Community Fund |
|
$ 100,000 |
NHS Charities Together |
|
$ 100,000 |
Northwell Health's COVID-19 Emergency Fund |
|
$ 100,000 |
NYU Langone |
|
$ 100,000 |
Off Their Plate |
|
$ 100,000 |
Oxfam India |
|
$ 100,000 |
Philippine Disaster Resilience Foundation |
|
$ 100,000 |
Red Hook Initiative |
|
$ 100,000 |
Rosetree Trust |
|
$ 100,000 |
Royal College of Nursing Foundation |
|
$ 100,000 |
RVNAhealth |
|
$ 100,000 |
Second Harvest |
|
$ 100,000 |
Sempre Con Voi (Always with You) |
|
$ 100,000 |
St Michael’s House |
|
$ 100,000 |
TBD 1 |
|
$ 100,000 |
TBD 2 |
|
$ 100,000 |
TBD 3 |
|
$ 100,000 |
TCF Bank |
|
$ 100,000 |
The Care Workers Charity |
|
$ 100,000 |
The River Fund New York |
|
$ 100,000 |
The United Way of Central Indiana COVID-19 Relief Fund |
|
$ 100,000 |
The World Health Organization (WHO) |
|
$ 100,000 |
Trinity's Services & Food for the Homeless |
|
$ 100,000 |
The Trussell Trust |
|
$ 100,000 |
UNICEF |
|
$ 100,000 |
UR Medicine Home Care’s Meals on Wheels |
|
$ 100,000 |
URMC COVID-19 Emergency Fund |
|
$ 100,000 |
Valpo Surf Project, Inc. |
|
$ 100,000 |
Volunteers of Legal Service |
|
$ 100,000 |
Our Dream Their Smile |
|
$ 100,000 |
West Side Campaign Against Hunger |
|
$ 100,000 |
Women United in Philanthropy |
|
$ 100,000 |
Women's Center of Greater Danbury |
|
$ 100,000 |
|
|
|
Jefferies Group LLC is the largest independent, global, full-service investment banking firm headquartered in the U.S. Focused on serving clients for nearly 60 years, Jefferies is a leader in providing insight, expertise and execution to investors, companies and governments. Our firm provides a full range of investment banking, advisory, sales and trading, research and wealth management services across all products in the Americas, Europe and Asia. Jefferies Group LLC is a wholly owned subsidiary of Jefferies Financial Group Inc. (NYSE: JEF), a diversified financial services company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005663/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
